KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pfizer (PFE) Shares Outstanding (2018 - 2026)

Pfizer has reported Shares Outstanding over the past 16 years, most recently at $9.6 billion for Q1 2026.

  • Quarterly Shares Outstanding changed 0.22% to $9.6 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.6 billion through Mar 2026, changed 0.22% year-over-year, with the annual reading at $9.6 billion for FY2025, 0.29% changed from the prior year.
  • Shares Outstanding was $9.6 billion for Q1 2026 at Pfizer, roughly flat from $9.6 billion in the prior quarter.
  • Over five years, Shares Outstanding peaked at $9.6 billion in Q1 2026 and troughed at $9.5 billion in Q2 2022.
  • The 5-year median for Shares Outstanding is $9.6 billion (2024), against an average of $9.6 billion.
  • Year-over-year, Shares Outstanding rose 0.7% in 2023 and then grew 0.22% in 2026.
  • A 5-year view of Shares Outstanding shows it stood at $9.5 billion in 2022, then increased by 0.45% to $9.6 billion in 2023, then rose by 0.32% to $9.6 billion in 2024, then rose by 0.29% to $9.6 billion in 2025, then rose by 0.21% to $9.6 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Shares Outstanding are $9.6 billion (Q1 2026), $9.6 billion (Q4 2025), and $9.6 billion (Q3 2025).